Section 1 - General Aspects of Medicinal Chemistry Section 2 - Lead Compound Discovery Strategies Section 3 - Primary Exploration of Structure-Activity Relationships Section 4 - Substituents and Functions: Qualitative and Quantitative Aspects of Structure-Activity Relationships Section 5 - Spatial Organization, Receptor Mapping and Molecular Modeling Section 6 - Chemical Modifications Influencing the Pharmacokinetic Properties Section 7 - Pharmaceutical and Chemical Means to Solubility and Formulation Problems
List of Contributors
Anne Badel, UMR-S973, MTi, University Paris Diderot, Paris, France
Patrick Bazzini, PC SAS, Bd Gonthier d'Andernach, Illkirch, France
Frans M. Belpaire, Heymans Institute for Pharmacology, Gent, Belgium
Alexandre Borrel
University of Helsinki, Helsinki, Finland
UMR-S973, MTi, University Paris Diderot, Paris, France
Koen Boussery, Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Gent University, Gent, Belgium
Christopher Brice, Consultant, Luthi & Co., Intellectual Property Law Offices, of Tel Aviv, Israel
Anne-Claude Camproux, UMR-S973, MTi, University Paris Diderot, Paris, France
David Cavalla, Numedicus Ltd, Cambridge, England
Paola Ciapetti, Head of Medicinal Chemistry, Novalyst Discovery, Illkirch, Cedex, France
Hongming Chen, Chemistry Innovation Centre, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
Yong Mi Choi-Sledeski, Sanofi, Boston, MA, USA
Bernd Clement, Pharmaceutical Institute, Christian Albrechts-University, Gutenbergstraße, Kiel, Germany
Gordon M. Cragg, NIH Special Volunteer, Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, United States National Cancer Institute, Frederick, Maryland, USA
Patrick M. Dansette, Laboratoire de Chimie et Biochimie Pharmacologique et Toxicologique, Université Paris Descartes, Sorbonne Paris Cité, Paris
Pierre deMontigny, Sanofi, Waltham, MA, U.S.A
Ji-Cui Dong, INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
Iain G. Dougall, IGD Consultancy Ltd, Loughborough, Leics, UK
Ola Engkvist, Chemistry Innovation Centre, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
Bernard Faller, Novartis Pharma AG, Werk Klybeck Klybeckstrasse, Basel, Switzerland
Bennett T. Farmer, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
Delphine Flatters, UMR-S973, MTi, University Paris Diderot, Paris, France
Bruno Galli, Novartis Pharma AG, Lichtstrasse, Basel, Switzerland
Colette Geneix, UMR-S973, MTi, University Paris Diderot, Paris, France
Bruno Giethlen, Novartis Pharma AG, Basel, Switzerland
Serge Grisoni, Pierre Fabre Research Institute, Toulouse, Cédex, France
Gerhard Gross, Scientific Director at Janssen in Beerse, Belgium
David Harris, Sanofi, Waltham, MA, U.S.A
Yuichi Hashimoto, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan
Chris Ho, Sanofi, Waltham, MA, U.S.A
Andrew L. Hopkins, College of Life Sciences, University of Dundee, Dundee, Scotland, UK
Hiba Abi Hussein, UMR-S973, MTi, University Paris Diderot, Paris, France
Peter Imming, Institut fuer Pharmazie, Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany
Minoru Ishikawa, Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan
Tim Jonckers, Janssen Research & Development Janssen Infectious Diseases - Diagnostics BVBA, Turnhoutseweg, Beerse, Belgium
Sabine Kopp, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
David G.I. Kingston, Department of Chemistry and the Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia, USA
Thierry Kogej, Chemistry Innovation Centre, Discovery Sciences, AstraZeneca R&D, Mölndal, Sweden
Sophie Lasseur, INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
Dominique Lesuisse, Lead Generation Board, Sanofi, AVENUE PIERRE BROSSOLETTE, CHILLY MAZARIN - France
Harvey Lieberman, Sanofi, Waltham, MA, USA
Richard Luthi, Founding partner, Luthi & Co., Intellectual Property Law Offices, of Tel Aviv, Israel
Anne-Christine Macherey, Prévention du Risque Chimique, Gif sur Yvette, France
André Mann, LAAS-CNRS, Université Louis Pasteur, Strasbourg, France
Raffaella G. Balocco Mattavelli, INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
Christophe Morice, Prestwick Chemical Inc., Boulevard Gonthier, Illkirch, France
Richard Morphy, Eli Lilly, Erl Wood Manor, Windlesham, Surrey, UK
David J. Newman, NIH Special Volunteer, Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, United States National Cancer Institute, Frederick, Maryland, USA
Anne Olivier, Sanofi-Aventis Recherche et Développement, Chilly-Mazarin, France
Michel Petitjean, UMR-S973, MTi, University Paris Diderot, Paris, France
Pierre Raboisson, Janssen Infectious Diseases and Diagnostics BVBA, Beerse, Belgium
Zoran Rankovic, Eli Lilly, Indianapolis, IN, USA
Leslie Regad, UMR-S973, MTi, University Paris Diderot, Paris, France
Allen B. Reitz, Fox Chase Chemical Diversity Center, Inc., Doylestown, PA, USA
Bernd U. Riebesehl, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland
Jean-Philippe Rocher, Pierre Fabre Research Institute, Castres, France
Tiago Rodrigues, Swiss Federal Institute of Technology (ETH), Department of Chemistry and Applied Biosciences, Zürich, Switzerland
A. Romeo, INN Programme, World Health Organization, Geneva Essential Medicines and Health Products, Regulation of Medicines and Other Health, Technologies, Technologies Standards and Norms
Jean-Michel Rondeau, Novartis Institutes for BioMedical Research, Basel, Switzerland
Laurent Schaeffer, Prestwick Chemical Inc., Boulevard Gonthier, Illkirch, France
Jean-Michel Scherrmann, Department of Pharmaceutical Sciences, University Paris...
